ArticleFrontiers in immunology2026
Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer (OC) is a highly heterogeneous disease, and its metabolic characteristics also exhibit heterogeneity. However, the specific metabolic pathways that play a critical role in OC metabolism remain unclear. Additionally, the significance of genes related to the metabolic pathways in the prognosis and therapeutic outcomes has not been clearly defined. Methods: In this study, we utilized the Cancer Genome Atlas Program (TCGA), Genotype-Tissue Expression (GTEx), and multiple Gene Expression Omnibus (GEO) datasets to perform gene set enrichment analysis (GSEA) on 84 metabolic pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG). Through robust rank aggregation (RRA) analysis, we identified the most significantly altered metabolic pathways. By constructing the most robust machine learning model using genes related to the most significantly altered metabolic pathways and combining it with single-cell sequencing analysis results, kinesin family member 1A (KIF1A) was selected as the gene for subsequent biological level studies. Results: We identified oxidative phosphorylation (OXPHOS) as one of the core metabolic pathways in OC. The OXPHOS-related gene signature (OPRGS) was built using the random survival forest (RSF) and supervised principal components (SuperPC) methods, which emerges as a comparatively reliable risk factor for OC. Patients with high-risk scores exhibited higher ESTIMATE stromal-related scores, a significant positive correlation with tumor-associated fibroblasts, higher tumor immune dysfunction and exclusion scores, and lower programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) immunophenoscores in the TCGA cohort, suggesting an immunosuppressive tumor microenvironment (TME) based on bioinformatic predictions. Additionally, higher OPRGS was associated with lower cancer stemness indices, resistance to paclitaxel but sensitivity to carboplatin, revealing complex biological behaviors of the tumor. Further analysis showed that high OPRGS were also correlated with high scores in cancer-related hallmark signaling pathways, such as Notch, angiogenesis, and epithelial-mesenchymal transition signaling pathways. By integrating single-cell RNA sequencing data, we identified KIF1A as a key gene for further investigation. Our findings indicated that KIF1A was upregulated in OC cell lines and might promote cell proliferation, invasion, and migration. Conclusion: This study constructed a new OPRGS for OC. It may serve as a potential indicator for predicting prognosis, immune infiltration, and chemotherapy drug sensitivity in OC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.